Skip to main content
. 2021 Mar 15;11:615986. doi: 10.3389/fonc.2021.615986

Figure 6.

Figure 6

MR images of the representative cases. (A–J) A 26-year-old female patient with DF of right calf muscle with imatinib treatment of (arrows). Pre-therapy MR images refer to examination before imatinib treatment. Pre-therapy (A, F) diameter, 113.0 mm; On T2WI, VT = 162,695 mm3, VHI = 97,617 mm3, HI = 60% (grade = 2); On T1 CE, VT = 163,750 mm3, VHI = 106,438 mm3, HI = 65% (grade = 2). Segmentation of VT (B, G, red zone) and segmentation of VHI (C, H, green zone). Second follow-up at 8 months since imatinib treatment (D, I) diameter, 112.0 mm indicate a 0.9% decrease in tumor size. The tumor response assessment is SD, according to RECIST1.1. Fourth follow-up at 15 months since imatinib treatment (E, J) diameter, 105.0 mm indicate a 7.1% decrease in tumor size as well as a decrease in T2 and T1 CE signal intensity. The tumor response assessment is SD, according to RECIST1.1. During 15 months of follow-up during imatinib treatment, there was no evidence of progression.